首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   5191篇
  免费   233篇
  国内免费   25篇
耳鼻咽喉   55篇
儿科学   135篇
妇产科学   80篇
基础医学   696篇
口腔科学   508篇
临床医学   335篇
内科学   1144篇
皮肤病学   51篇
神经病学   507篇
特种医学   176篇
外科学   659篇
综合类   35篇
一般理论   2篇
预防医学   402篇
眼科学   55篇
药学   371篇
中国医学   30篇
肿瘤学   208篇
  2024年   3篇
  2023年   39篇
  2022年   102篇
  2021年   211篇
  2020年   115篇
  2019年   160篇
  2018年   196篇
  2017年   134篇
  2016年   128篇
  2015年   198篇
  2014年   236篇
  2013年   276篇
  2012年   464篇
  2011年   467篇
  2010年   255篇
  2009年   200篇
  2008年   338篇
  2007年   367篇
  2006年   331篇
  2005年   283篇
  2004年   240篇
  2003年   241篇
  2002年   205篇
  2001年   26篇
  2000年   12篇
  1999年   22篇
  1998年   19篇
  1997年   23篇
  1996年   16篇
  1995年   10篇
  1994年   12篇
  1993年   7篇
  1992年   8篇
  1991年   6篇
  1990年   6篇
  1989年   7篇
  1988年   8篇
  1987年   4篇
  1986年   4篇
  1985年   11篇
  1984年   5篇
  1983年   4篇
  1982年   10篇
  1981年   5篇
  1980年   4篇
  1979年   5篇
  1974年   2篇
  1973年   2篇
  1936年   2篇
  1922年   2篇
排序方式: 共有5449条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.

Introduction

In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.

Methods

Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.

Results

Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.

Conclusions

These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population.  相似文献   
5.
6.
7.
8.
Cecal intubation is a critical aspect of effective, complete colonoscopy. Difficult colonoscopy is most often considered as one in which it is challenging or impossible to reach the cecum. It may be a common occurrence due to patient and/or endoscopist factors. Incomplete colonoscopies should be avoided, since patients in this context present an important prevalence of lesions that escape examination. The approach to successful cecal intubation should depend on characterization of the problem as redundant colon or difficult sigmoid colon. Most patients with a prior incomplete colonoscopy can be colonoscoped successfully, if careful attention is paid to technique, using a variety of scopes, colonoscopy methods and additional equipment. Sufficient time should be allotted to make the attempt.  相似文献   
9.
10.
OBJECTIVE: The objective of this study was to radiographically quantify bone density and bone height preservation in tooth extraction alveolus filled with xenograft. STUDY DESIGN: The maxillary and mandibular fourth deciduous molars and fourth premolars of 6 minipigs were removed. Randomly, in 3 animals the right side was used as the test side and in the other 3 animals the left side was the test side. Intraoral radiographs were performed to compare the condition at the initial time and 3 months later. Measurements of bone height and bone density were performed using KS300 (Zeiss) software. RESULTS: After 3 months, there was a statistically significant smaller bone height loss for the test group. The test group presented a statistically greater bone density immediately after tooth extraction. However, after 3 months there was no statistically significant difference between the groups. CONCLUSIONS: The results suggest that treatment of postextraction alveolus with xenograft can preserve bone height initially but differences in bone density compared to when no xenograft is used are not sustained.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号